{
    "nct_id": "NCT04458259",
    "official_title": "A PHASE 1, OPEN-LABEL, MULTI-CENTER, DOSE-FINDING, PHARMACOKINETIC, SAFETY AND TOLERABILITY STUDY OF PF 07265807 IN PARTICIPANTS WITH SELECTED ADVANCED OR METASTATIC SOLID TUMOR MALIGNANCIES",
    "inclusion_criteria": "* At least one measurable (Parts 1-4) or non-measurable lesion (Parts 1-3), not previously irradiated, as defined by RECIST 1.1\n* ECOG Performance Status 0 or 1, 2 with approval\n* Adequate Bone Marrow Function\n* Adequate Renal Function\n* Adequate Liver Function\n* Resolved acute effects of any prior therapy\n* Able to provide adequate archival tumor tissue or freshly obtained tumor tissue (some participants will require mandatory pre- and on-treatment biopsy is part of the biomarker cohort).\n* Life expectancy of at least 3 months.\n* Part 1 and Part 2: Participants who are intolerant or resistant to standard treatment for selected solid tumors.\n* Part 3: Participants with advanced/metastatic RCC with a clear cell component and progressed with no standard therapy available.\n* Part 4, Cohort 1: Participants with NSCLC with METex14-skipping alteration(s) and progressed on at least 1 prior therapy.\n* Part 4, Cohort 2: Participants with MSS CRC with intermediate TMB and progressed with no satisfactory alternative treatment available, but has not received prior treatment with an anti-PD-(L)1 therapy.\n* Part 4, Cohort 3: Participants with metastatic gastric or GEJ adenocarcinoma that is PD-L1 positive that has progressed on at least 2 but no more than 3 prior chemotherapy regiments, but has not received prior treatment with an anti-PD-(L)1 therapy.\n* Part 4, Cohort 4: Participants with metastatic RCC with a clear cell component with IMDC intermediate or poor risk that have not received any prior systemic therapy for metastatic disease.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Known active uncontrolled or symptomatic CNS metastases.\n* Any other active malignancy within 2 years prior to enrollment.\n* Major surgery within 6 weeks, radiation therapy within 4 weeks, systemic anti-cancer therapy within 2 week or 5 half-lives (4 weeks or 5 half-lives for antibody therapies or investigational drug(s) taken on another study) prior to study entry.\n* Active or history of autoimmune disease requiring >10mg/day prednisone or other concurrent immunosuppressive therapy.\n* Active, uncontrolled infection (controlled HBV, HCV, HIV/AIDS may be allowed) as defined in protocol.\n* Retinal or other serious ophthalmic disorders as defined in protocol.\n* Clinically significant cardiac disease as defined in protocol.\n* Uncontrolled HTN that cannot be controlled by medications.\n* Inability to consume or absorb study drug.\n* Known or suspected hypersensitivity to PF-07265807.\n* Prohibited concomitant medications as defined in protocol.\n* Active inflammatory GI disease, uncontrollable chronic diarrhea, or previous gastric resection or lap band surgery affecting absorption.\n* Active bleeding disorder.\n* Discontinuation of prior checkpoint inhibitor for treatment-related toxicity.\n* Experienced >= G3 treatment-related irAE with prior PD-(L)1 agent.\n* Prior treatment with selective AXL/MERTK inhibitors\n\nFor participants receiving sasanlimab:\n\n- Known history of non-infectious pneumonitis that required steroid treatment or current pneumonitis.",
    "miscellaneous_criteria": ""
}